clinical trial · NCT04533581
Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)
Kyowa Kirin Co., Ltd.·phase2·active not recruiting·n = 61
Indolent B-cell Non-Hodgkin's LymphomaME-401
brief summary
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ME-401 in the treatment of Japanese participants with Relapsed or Refractory indolent B-Cell Non-Hodgkin's Lymphoma.
started
Sep 17, 2020
primary completion
May 31, 2028
completion
May 31, 2028
last updated
Sep 11, 2025
official title
A Japanese Phase 2 Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol